lapatinib has been researched along with docetaxel in 3 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (docetaxel) | Trials (docetaxel) | Recent Studies (post-2010) (docetaxel) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 101 | 0 | 33 |
| Protein | Taxonomy | lapatinib (IC50) | docetaxel (IC50) |
|---|---|---|---|
| Tubulin beta-4A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta chain | Homo sapiens (human) | 0.5 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 0.5 | |
| Substance-K receptor | Homo sapiens (human) | 1.563 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 0.5 | |
| Growth hormone-releasing hormone receptor | Homo sapiens (human) | 0.0001 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 0.5 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 0.5 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Lou, L; Xie, F; Zhao, H; Zhao, L | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bailey-Downs, LC; Bastian, A; Disch, BC; Dybdal-Hargreaves, NF; Gangjee, A; Hamel, E; Ihnat, M; Mooberry, SL; Raghavan, S; Rohena, CC; Thorpe, JE; Zhang, X | 1 |
3 other study(ies) available for lapatinib and docetaxel
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Liver Neoplasms; Pyrimidines; Structure-Activity Relationship | 2009 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Solubility; Structure-Activity Relationship; Water | 2014 |